Exclusive agreements between GSK And Sabin Vaccine Institute for clinical stage Ebola vaccine

GSK and Sabin Vaccine Institute have an exclusive agreement in place for the development of vaccinations against Ebola Zaire, Ebola Sudan and Marbug virus.
Under the agreement, Sabin has exclusively licensed the technology for all three vaccines originally developed by the US Notational Institutes of Health and Okarios, (acquired in 2013 by GSK).
“The agreements with Sabin is an important next step to fighting against Ebola and Marbug Viruses.” Said Thomas Breuer, Chief medical Officer for GSK Vaccines. “Sabin can build on the progress we have delivered and increase the likelihood that these vaccines will prevent future outbreaks.”
Sabin have entered into an agreement with Research Collaboration Agreement with Vaccine Research Center to further develop the vaccines.